Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?

  • Review
  • Published:
Oncology Reviews

Abstract

Bladder cancer is the fourth most common cancer for men and the eighth most common cancer for women. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting the treatment is based on cisplatin chemotherapy regimens type MVAC, MVAC-HD or gemcitabine plus cisplatin. The standard treatment of muscle invasive operable bladder cancer (T2–T4) used widely was radical cystectomy with pelvic lymph nodes dissection; the anatomical extent of pelvic lymphadenectomy has not accurately been defined so far. However, in the last decade, the treatment of tumors was improved by the introduction of chemotherapy as part of the management of the disease. Neoadjuvant chemotherapy should be considered at first, as standard treatment of choice, before local treatment for patients with good performance status (0–1) and good renal function–glomerular filtration rate (GFR) >60 mL/min. For patients treated with primary surgery, adjuvant chemotherapy is a valuable option in the case of lymph nodes involvement. This brief review would provide the evidence of the role of neoadjuvant chemotherapy in the management of operable muscle invasive (T2–T4) bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics. CA Cancer J Clin 58(2):71–96

    Article  PubMed  Google Scholar 

  2. Bacon C (2005) Chemotherapy for bladder cancer. In: Waxman J (ed) Urological cancers. Springer, London, pp 145–155

    Google Scholar 

  3. Rathkopf D, Scher HI (2007) Multidisciplinary management of genitourinary malignancies. In: Alison MR (ed) The cancer handbook, 2nd edn edn. Wiley, London, pp 1432–1452

    Google Scholar 

  4. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055

    PubMed  CAS  Google Scholar 

  5. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7):1066–1073

    PubMed  Google Scholar 

  6. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646

    PubMed  CAS  Google Scholar 

  7. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54

    Article  PubMed  CAS  Google Scholar 

  8. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077

    Google Scholar 

  9. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N et al (1991) Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67:608–615

    Article  PubMed  CAS  Google Scholar 

  10. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, Escudero A, Jimenez Cruz F, Isorna S (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153((3 Pt 2)):964–973

    Article  PubMed  Google Scholar 

  11. Orsatti M, Curotto A, Canobbio L, Guarneri D, Scarpati D, Venturini M et al (1995) Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 33:173–178

    Article  PubMed  CAS  Google Scholar 

  12. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2901–2907

    PubMed  CAS  Google Scholar 

  13. Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155:1903–1906

    Article  PubMed  Google Scholar 

  14. Bassi P, Pagano F, Pappagallo G (1998) Neoadjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial. Eur Urol 33 (abstract 567)

  15. GISTV (Italian Bladder Cancer Study Group) (1996) Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother 8:345–346

    Google Scholar 

  16. (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354(9178):533–540

  17. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866

    Article  PubMed  CAS  Google Scholar 

  18. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmström PU, Nordic Urothelial Cancer Group (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425

    Article  PubMed  CAS  Google Scholar 

  19. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):189–199

    Article  Google Scholar 

  20. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29(16):2171–2177

    Google Scholar 

  21. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S et al (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6(10):1590–1596

    PubMed  CAS  Google Scholar 

  22. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145(3):459–464

    PubMed  CAS  Google Scholar 

  23. Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW et al (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148(2 Pt 1):302–306

    PubMed  Google Scholar 

  24. Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U et al (1995) Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153(1):47–52

    Article  PubMed  Google Scholar 

  25. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L et al (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152(1):81–84

    PubMed  CAS  Google Scholar 

  26. Bono AV, Benvenuti C, Gibba A (1997) Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital 11:5–8

    Google Scholar 

  27. Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155(2):495–499

    Article  PubMed  CAS  Google Scholar 

  28. Otto T, Bo¨rgemann C, Krege S (2001) Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1–2, M0)-a phase III study. Eur Urol 39(Suppl 5):147

    Google Scholar 

  29. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. (2008) On behalf of the Study Group Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. J Clin Oncol 26 (abstract 5023)

  30. Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. (2010) Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 28 (abstract LBA4518)

  31. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–206

    Article  Google Scholar 

  32. Stenzl A, Cowan NC, de Santis M, Kuczyk MA, Merseburger AS, Ribal MJ et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009–1018

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Mohammed Ismaili from the Department of Microbiology, Moulay Ismail University, Meknes, Morocco.

Conflict of interest

The authors have declared no conflict of interest.

Author information

Authors and Affiliations

  1. Centre d’oncologie, CHU Mohamed VI, Marrakech, Morocco

    Nabil Ismaili, Rhizlane Belbaraka, Abdelhamid Elomrani, Mouna Khouchani & Ali Tahri

  2. Institut National d’Oncologie, Rabat, Morocco

    Sanaa Elmajjaoui, Youssef Bensouda, Halima Abahssain, Wafa Allam, Zouhour Fadoukhair, Mohamed Mesmoudi, Rachid Tanz, Tarik Mahfoud, Yassir Sbitti, Noureddine Benjaafar & Hassan Errihani

Authors
  1. Nabil Ismaili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanaa Elmajjaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youssef Bensouda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rhizlane Belbaraka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Halima Abahssain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wafa Allam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zouhour Fadoukhair
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohamed Mesmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rachid Tanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tarik Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Abdelhamid Elomrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mouna Khouchani
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yassir Sbitti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Noureddine Benjaafar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hassan Errihani
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ali Tahri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil Ismaili.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ismaili, N., Elmajjaoui, S., Bensouda, Y. et al. Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. Oncol Rev 5, 185–189 (2011). https://doi.org/10.1007/s12156-011-0085-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-011-0085-0

Keywords

Search

Navigation